Group 1 - The company Tian Sheng New Materials (SZ 300169) reported a revenue of approximately 334 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 16.71% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 83.12 million yuan [1] - The basic earnings per share showed a loss of 0.255 yuan [1]

常州天晟新材料集团股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开公司第六届董事会第十四次会议、第六届监事会第十次会议审议通过 了《2025 年第三季度报告》。 为使投资者全面了解公司的经营成果和财务状况，公司《2025 年第三季度 报告》于 2025 年 10 月 30 日在中国证监会指定的创业板信息披露网站上披露， 请投资者注意查阅。 特此公告。 证券代码：300169 证券简称：天晟新材 公告编号：2025-046 常州天晟新材料集团股份有限公司 2025年第三季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 二〇二五年十月二十九日 常州天晟新材料集团股份有限公司 董事会 ...

证券代码：300169 证券简称：天晟新材 公告编号：2025-048 常州天晟新材料集团股份有限公司 关于2025年第三季度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《企业会计准则》《深圳证券交易所创业板股票上市规则》《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》以及公司会计 政策等有关规定，本着谨慎性原则，常州天晟新材料集团股份有限公司（以下简 称"公司"）对截至 2025 年 9 月 30 日合并报表范围内存在减值迹象的各项资产进 行减值测试，并根据测试结果，计提或冲回减值损失，合并报表层面最终核算结 果为计提减值损失。本次计提减值准备无需提交董事会、股东大会审议。 （二）本次计提资产减值损失的范围和总金额 一、本次计提资产减值损失情况概述 （一）本次计提资产减值损失的原因 2、资产减值损失 单位：万元 | 项目 | 本期计提金额（冲回以"-"列示） | | --- | --- | | 存货跌价损失及合同履约成本减值损失 | 665.68 | | 合同资产减值损失 | 34.16 | | 长 ...

Financial Performance - Revenue for Q3 2025 was ¥112,239,115.28, a decrease of 24.45% compared to the same period last year[5] - Net profit attributable to shareholders was -¥39,411,973.78, a decline of 1,030.44% year-over-year[5] - Basic and diluted earnings per share were both -¥0.1209, reflecting a decrease of 1,030.00% compared to the same period last year[5] - Total operating revenue for the current period was CNY 334,246,047.22, a decrease of 16.7% compared to CNY 401,310,550.97 in the previous period[20] - Net loss for the current period was CNY -84,382,697.32, compared to a net profit of CNY 7,476,428.09 in the previous period[21] - Basic and diluted earnings per share for the current period were both CNY -0.2550, compared to CNY 0.0257 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥769,963,486.68, down 9.83% from the previous year[5] - The company's total assets decreased to CNY 769,963,486.68 from CNY 853,923,855.32, a decline of 9.8%[19] - Total liabilities remained relatively stable at CNY 804,734,266.12, compared to CNY 804,041,752.77 in the previous period[19] - The company's equity attributable to shareholders decreased to CNY -30,620,858.64 from CNY 52,764,404.42, indicating a significant decline[19] Cash Flow - The net cash flow from operating activities increased by 70.50% year-to-date, totaling -¥25,717,927.44[10] - Operating cash flow for the current period was -25,717,927.44 CNY, an improvement from -87,177,147.11 CNY in the previous period, indicating a reduction in cash outflow[22] - Total cash inflow from investment activities increased significantly to 126,431,995.91 CNY, compared to 25,165,038.31 CNY in the prior period[22] - Net cash flow from financing activities was -62,773,345.87 CNY, worsening from -35,242,239.71 CNY year-over-year[23] - The company reported a net increase in cash and cash equivalents of 6,941,089.33 CNY, contrasting with a decrease of -135,122,801.31 CNY in the previous period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,592[12] - The top 10 shareholders hold a total of 50.82% of the shares, with Wu Haizhou holding 7.80% and Sun Jian holding 3.53%[12] Investment and Expenses - Long-term equity investments decreased by ¥5.31 million due to impairment provisions[9] - The company reported a 33.57% increase in financial expenses year-to-date, primarily due to higher interest expenses[9] - Research and development expenses were CNY 8,664,962.51, slightly up from CNY 8,224,021.60, reflecting ongoing investment in innovation[20] - The company experienced a 213.94% increase in estimated liabilities, primarily due to new expected litigation compensation[9] Other Financial Metrics - The company completed the sale of its wholly-owned subsidiary Xingyue Capital for a transfer price of RMB 2.8 million, effective September 26, 2025[14] - The company's cash and cash equivalents increased to RMB 47,594,771.64 from RMB 40,104,670.31, representing a growth of approximately 18.5%[17] - Accounts receivable decreased to RMB 137,301,170.74 from RMB 201,977,159.80, a decline of about 32%[17] - Inventory decreased to RMB 62,453,144.53 from RMB 66,069,342.93, reflecting a reduction of approximately 5.5%[17] - Non-current assets include fixed assets valued at RMB 297,089,046.86, down from RMB 305,898,222.86, indicating a decrease of about 2.6%[17] - The company has a long-term equity investment valued at RMB 5,313,975.12, which remains unchanged[17] - The company has reported a total current asset of RMB 294,546,064.81, down from RMB 366,640,708.68, a decrease of approximately 19.6%[17] Audit and Compliance - The third quarter financial report was not audited, indicating a potential area for further scrutiny[24]

Group 1 - The company is currently focusing on enhancing its main business operations and is making adjustments and divestments in non-core business segments or subsidiaries that are continuously incurring losses to reduce their impact on the profitability of the main business [1] - The company's housing expropriation and compensation matters are expected to have a positive impact on its financial indicators after the relocation is completed [1]

Market Overview - The Shanghai Composite Index closed at 3865.23 points, with a decline of 0.62% [1] - The total trading volume of A-shares reached 25,965.85 billion yuan [1] Technical Analysis - A total of 114 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Hongxing Co., Ltd. with a distance of -2.60% [1] - Huayi Technology with a distance of -2.54% [1] - Top Group with a distance of -2.48% [1] Individual Stock Performance - Hongxing Co., Ltd. (001209) saw a decline of 2.11% with a trading turnover of 4.66% [1] - Huayi Technology (688071) experienced a drop of 6.84% with a trading turnover of 5.55% [1] - Top Group (601689) fell by 6.13% with a trading turnover of 2.80% [1] - Other notable declines include: - Green Harmonic (688017) down 7.05% [1] - Fangzheng Electric (002196) down 1.99% [1] - Zhongyou Technology (688648) down 5.32% [1] Additional Stock Movements - Several stocks showed minor declines, including: - ST Huayi (600360) down 0.49% [2] - Olin Biotech (688319) down 7.06% [2] - Qinchuan IoT (688528) down 1.43% [2] - Stocks with slight increases include: - Gujing (000596) up 2.81% [2]

证券代码：300169 证券简称：天晟新材 公告编号：2025-045 常州天晟新材料集团股份有限公司（以下简称"公司"）与被上诉人国家知识 产权局及一审第三人威海维赛新材料科技有限公司、保定维赛新材料科技股份有 限公司、望都维赛新材料科技有限责任公司、维赛（威海）科技发展有限公司、 维赛（江苏）复合材料科技有限公司的发明专利权无效行政纠纷一案, 最高人民 法院已终审判决。现将具体情况公告如下： 常州天晟新材料集团股份有限公司 关于重大诉讼事项进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 1、案件（发明专利权无效行政纠纷案）所处的诉讼阶段：终审判决。 2、公司所处的当事人地位：上诉人（一审原告、专利权人）。 3、涉案的金额：不涉及。 4、对公司损益产生的影响：发明专利权无效行政纠纷一案，最高人民法院 已终审判决，此诉讼对公司本期利润或期后利润暂无重大影响。公司将及时履行 信息披露义务，敬请投资者注意投资风险。 一、诉讼案件的基本情况 公司就威海维赛新材料科技有限公司、保定维赛新材料科技股份有限公司、 望都维赛新材料科技有限责任公司、维 ...

Core Viewpoint - Tian Sheng New Materials announced the completion of the sale of its wholly-owned subsidiary, Xingyue Capital, for 2.8 million RMB, marking a strategic exit from the securities business [1] Group 1: Transaction Details - Tian Sheng Hong Kong signed a share purchase agreement with Li Nan, Cao Zheng, and Wang Jiyang to transfer 100% equity of Xingyue Capital [1] - The transfer price for the equity was set at 2.8 million RMB [1] - The transaction was completed on September 26, 2025, with all conditions met as per the delivery confirmation documents [1] Group 2: Impact on Company Structure - Following the completion of the equity transfer, Tian Sheng will no longer hold any direct or indirect equity in Xingyue Capital and its subsidiary, Tian Sheng Securities [1] - As a result, Xingyue Capital and Tian Sheng Securities will be excluded from the company's consolidated financial statements [1] - The company will cease to engage in securities-related business activities [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易概述 证券代码：300169 证券简称：天晟新材 公告编号：2025-044 常州天晟新材料集团股份有限公司 关于出售子公司全部股权进展暨完成交割的公告 2025 年 6 月 30 日，常州天晟新材料集团股份有限公司（以下简称 "公司"） 下属全资子公司天晟新材料（香港）有限公司（以下简称"天晟香港"）与李楠、 曹征、王继杨签署了《关于兴岳资本有限公司的股份买卖协议》，天晟香港将其 持有的兴岳资本有限公司 100%的股权转让给李楠、曹征、王继杨，转让价格为 280 万元人民币。兴岳资本有限公司的主要资产为其持有的天晟证券有限公司 100%的股权。具体内容详见公司 2025 年 6 月 3 日、2025 年 7 月 1 日披露的《关 于终止股权转让框架协议及重新签署框架协议的提示性公告》（公告编号： 2025-034）、《关于出售子公司全部股权的公告》（公告编号：2025-035）。 二、交易进展及交割完成情况 二〇二五年九月二十九日 截至本公告披露日，根据交易各方签署的交割确认文件，《关于兴岳资本有 限公 ...

Market Overview - The Shanghai Composite Index closed at 3821.83 points, with a decline of 0.18% [1] - The total trading volume of A-shares reached 25,184.71 billion yuan [1] Technical Analysis - A total of 171 A-shares experienced a death cross, where the 5-day moving average fell below the 10-day moving average [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Innovation Medical: 5-day MA at 22.60 yuan, 10-day MA at 23.25 yuan, a difference of -2.80% [1] - Xiangyu Medical: 5-day MA at 54.48 yuan, 10-day MA at 55.33 yuan, a difference of -1.54% [1] - Northern Long Dragon: 5-day MA at 122.21 yuan, 10-day MA at 123.92 yuan, a difference of -1.38% [1] Stock Performance - Key stocks with notable declines include: - Innovation Medical: down 2.97% with a turnover rate of 16.99% [1] - Xiangyu Medical: down 5.95% with a turnover rate of 2.14% [1] - Northern Long Dragon: down 2.23% with a turnover rate of 20.67% [1] - Other stocks with significant declines include: - Aorui: down 5.25% [1] - Changbai Mountain: down 7.15% [1] - Hengbao Shares: down 6.73% [1]